Search

Your search keyword '"Cinieri, Enrico"' showing total 4 results
Start Over Author "Cinieri, Enrico" Search Limiters Full Text
4 results on '"Cinieri, Enrico"'

2. A new high-speed digital relay protection of the 3-kVdc electric railway lines

Author

Cinieri, Enrico, Fumi, Alvaro, Salvatori, Vittorio, and Spalvieri, Claudio

Subjects
Algorithms -- Usage, Electric railroads -- Equipment and supplies, Electric fault location -- Methods, Relays -- Design and construction, Railroads -- Switches, Railroads -- Design and construction, Electric power systems -- Protection and preservation, Electric power systems -- Research, Algorithm, Business, Computers, Electronics, Electronics and electrical industries
Abstract

In Italy, the increase of railway traffic and of the power demand by the trains, especially the high-speed trains, has caused a continuous increase of the currents through the electric traction lines rated at 3 kVdc. As a consequence, in some cases, the load currents may approach the value of the fault currents for faults located far from the supply stations. The detection of the faults in such a situation has become difficult for the electromechanical protections at present in operation in Italy in the lines above. In addition, transient phenomena related to the train absorption, frequently cause untimely trippings of the protections above. For such a reason, in the years 1999-2000, a field test campaign was performed in the 3-kVdc lines Campoleone-Cisterna and Farneta-Montallese in Italy, in order to investigate the phenomena that lead to the untimely trippings above. On the basis of the field test campaign, it was found that such an inconvenience is related to the inner characteristics of the electromechanical protections in use. A digital protection, operating on new protective algorithms, was thus set up and thereafter put in operation in the years 2003-2004. This paper presents the basic principles of the new protection above and the results of the first two years of operation. Index Terms--Digital relay protection, electric railways, fault protection.

Published
2007

4. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

Author

Andrea Onetti Muda, Guido Giordano, Gianni Simone, Pietro Micheli, C. Barone, Giacomo Cartenì, Fabiana Tatangelo, Laura Longhitano, Vincenzo Rosario Iaffaioli, Alessandra Cassano, M. Biglietto, Anna Nappi, Sabrina Rossi, A.R. Bordonaro, A. Rinaldi, Francesco Sponziello, G. Modoni, GabrieleDi Maggio, Matilde Lambiase, Oscar Nappi, Claudia Cardone, Antonella Marino, Mirko Montrone, Sandro Barni, Michele Orditura, Antonio Febbraro, Paolo Graziano, Saverio Cinieri, Guglielmo Nasti, Fortunato Ciardiello, Evaristo Maiello, D. Rizzi, Vincenzo Sforza, Stefano Cordio, F. De Vita, Erika Martinelli, S. Romito, Vincenzo Montesarchio, Giuseppe Tonini, Annamaria Sebastio, Salvatore Pisconti, Nicola Normanno, Tiziana Guarino, Giuseppe Colucci, Francesco Giuliani, Anna Maria Rachiglio, Gerardo Botti, Nicoletta Chicchinelli, Tiziana Latiano, Teresa Troiani, Vito Lorusso, Michele Aieta, Silvana Leo, Giuseppe Grimaldi, Eugenio Tommaselli, Luigi Leo, Cinzia Chiarazzo, Mario Manusia, Martinelli, E, Cardone, C, Troiani, T, Normanno, N, Pisconti, S, Sforza, V, Bordonaro, A R, Rachiglio, A M, Lambiase, M, Latiano, T P, Modoni, G, Cordio, S, Giuliani, F, Biglietto, M, Montesarchio, V, Barone, C, Tonini, G, Cinieri, Enrico, Febbraro, A, Rizzi, D, De Vita, F, Orditura, M, Colucci, G, Maiello, E, and Ciardiello, F

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Population, colorectal cancer, medicine.disease_cause, elderly, FOLFIRI, FOLFOX, Internal medicine, cetuximab, Medicine, education, neoplasms, Original Research, education.field_of_study, Cetuximab, business.industry, digestive system diseases, Oxaliplatin, Irinotecan, Tolerability, NGS, KRAS, business, medicine.drug
Abstract

In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin (FOLFOX) with or without cetuximab until progression. Limited data are available on the efficacy and safety of anti-epidermal growth factor receptor (anti-EGFR) agents on elderly patients with mCRC. In the current study we evaluated the efficacy and safety of FOLFIRI plus cetuximab in age-defined subgroups. Background: In the cetuximab after progression in KRAS wild-type colorectal cancer patients ( CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin (FOLFOX) with or without cetuximab until progression. Limited data are available on the efficacy and safety of anti-epidermal growth factor receptor (anti-EGFR) agents on elderly patients with mCRC. In the current study we evaluated the efficacy and safety of FOLFIRI plus cetuximab in age-defined subgroups.Methods: A post-hoc analysis was performed in CAPRI trial patients; outcomes (progression-free survival (PFS), overall response rate (ORR), safety) were analysed by agegroups and stratified according to molecular characterisation. 3 age cut-offs were used to define the elderly population (>= 65; >= 70 and >= 75 years).Results: 340 patients with mCRC were treated in first line with FOLFIRI plus cetuximab. Among those, 154 patients were > 65 years, 86 > 70 years and 35 > 75 years. Next-generation sequencing (NGS) was performed in 182 patients. Among them, 87 patients were > 65 years, 46 > 70 and 17 > 75. 104 of 182 patients were wild type (WT) for KRAS, NRAS, BRAF, PIK3CA genes. In the quadruple WT group, 51 patients were >= 65 years; 29 were >= 70; 9 were >= 75. Median PFS was similar within the age-subgroups in the intention-to-treat population, NGS cohort and quadruple WT patients, respectively. Likewise, ORR was not significantly different among age-subgroups in the 3 populations. Safety profile was acceptable and similarly reported among all age-groups, with the exception of grade >= 3 diarrhoea (55% vs 25%, p=0.04) and neutropaenia (75% vs 37%, p=0.03) in patients >= 75 years and grade >= 3 fatigue (31% vs 20%, p=0.01) in patients < 75 years.Conclusions: Tolerability of cetuximab plus FOLFIRI was acceptable in elderly patients. Similar ORR and PFS were observed according to age-groups. No differences in adverse events were reported among the defined subgroups with the exception of higher incidence of grade >= 3 diarrhoea and neutropaenia in patients >= 75 years and grade >= 3 fatigue in patients < 75 years.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results